KR102297398B1 - Composition for health food for improving of respiratory diseases caused by fine dust comprising extract of Liriope platyphylla, Glycyrrhiza uralensis and Aronia as an effective component - Google Patents
Composition for health food for improving of respiratory diseases caused by fine dust comprising extract of Liriope platyphylla, Glycyrrhiza uralensis and Aronia as an effective component Download PDFInfo
- Publication number
- KR102297398B1 KR102297398B1 KR1020200027571A KR20200027571A KR102297398B1 KR 102297398 B1 KR102297398 B1 KR 102297398B1 KR 1020200027571 A KR1020200027571 A KR 1020200027571A KR 20200027571 A KR20200027571 A KR 20200027571A KR 102297398 B1 KR102297398 B1 KR 102297398B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- aronia
- licorice
- fine dust
- maekmundong
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 113
- 241001444063 Aronia Species 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 239000000428 dust Substances 0.000 title claims abstract description 28
- 241001532026 Liriope muscari Species 0.000 title claims abstract description 13
- 240000008917 Glycyrrhiza uralensis Species 0.000 title claims abstract description 12
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 title claims abstract description 12
- 208000023504 respiratory system disease Diseases 0.000 title description 7
- 235000013402 health food Nutrition 0.000 title description 3
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- 241000202807 Glycyrrhiza Species 0.000 claims description 45
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 45
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 45
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 45
- 229940010454 licorice Drugs 0.000 claims description 45
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 3
- 108090001007 Interleukin-8 Proteins 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 3
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 230000003833 cell viability Effects 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 229940069445 licorice extract Drugs 0.000 description 8
- 239000008213 purified water Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000006433 tumor necrosis factor production Effects 0.000 description 4
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 3
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000021995 interleukin-8 production Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- -1 for example Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241001448331 Liriope spicata Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- BXTNNJIQILYHJB-GFCCVEGCSA-N Methylophiopogonanone A Natural products C1=C2OCOC2=CC(C[C@@H]2COC3=C(C)C(O)=C(C(=C3C2=O)O)C)=C1 BXTNNJIQILYHJB-GFCCVEGCSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- QBRLTNYECODTFP-NSHDSACASA-N Ophiopogonanone A Natural products O=C1[C@@H](Cc2cc3OCOc3cc2)COc2c1c(O)c(C)c(O)c2 QBRLTNYECODTFP-NSHDSACASA-N 0.000 description 1
- QBRLTNYECODTFP-UHFFFAOYSA-N Ophiopogonanone A Chemical compound C1=C2OCOC2=CC(CC2COC3=CC(O)=C(C(=C3C2=O)O)C)=C1 QBRLTNYECODTFP-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- AUTZLTCWRDPAPV-UHFFFAOYSA-N methylophiopogonone A Chemical compound C1=C2OCOC2=CC(CC2=COC3=C(C)C(O)=C(C(=C3C2=O)O)C)=C1 AUTZLTCWRDPAPV-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920005547 polycyclic aromatic hydrocarbon Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052815 sulfur oxide Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 맥문동 추출물, 감초 추출물 및 아로니아 추출물을 유효성분으로 포함하는 미세먼지에 의한 기관지 염증 질환의 개선용 건강 기능 식품 조성물에 관한 것으로서, 보다 구체적으로, 본 발명에 따른 조성물은 미세먼지로 유발되는 호흡기 질환 중 기관지 염증 질환에 대한 개선용 건강 기능 식품에 포함될 수 있는 조성물에 관한 것이다.
The present invention relates to a health functional food composition for improving bronchial inflammatory diseases caused by fine dust comprising a maekmundong extract, a licorice extract and an aronia extract as active ingredients, and more specifically, the composition according to the present invention is caused by fine dust It relates to a composition that can be included in a functional food for improvement of bronchial inflammatory diseases among respiratory diseases.
미세먼지(Particulate Matter, PM)란 공기 중 장기간 떠다니는 미세한 먼지를 말하며, 입경 2.5 ㎛ 이하의 크기는 초미세먼지로 분류된다. 지난 수십 년간 우리나라의 급격한 산업화 및 공업화로 인해 환경이 지속적으로 악화되어 왔으며, 최근 중국의 높은 석탄 의존도와 급격한 경제 성장과 더불어 스모그 현상이 지속적으로 증가하여 미세먼지의 발생이 빈번해지고 있다. 황산화물, 질소산화물, 납 등의 유해물질들이 포함된 미세먼지는 호흡기 및 피부를 통해 인체 내에 침투할 수 있으며, 폐기능 감소, 천식 악화, 만성기관지염 발생 등 호흡기계 관련 질환을 야기하며, 심근경색, 협심증, 부정맥 등 심혈관계 관련 질환의 발생을 증가시키는 것으로 알려져 있다(김오식 외, 2009, ReSEAT 분석보고서). Particulate Matter (PM) refers to fine dust that floats in the air for a long time, and particles with a particle diameter of 2.5 μm or less are classified as ultra-fine dust. The environment has been continuously deteriorating due to rapid industrialization and industrialization of Korea over the past several decades. Fine dust containing harmful substances such as sulfur oxides, nitrogen oxides, and lead can penetrate into the human body through the respiratory system and skin, and cause respiratory system-related diseases such as decreased lung function, worsening of asthma, and chronic bronchitis, and myocardial infarction. , is known to increase the incidence of cardiovascular-related diseases such as angina and arrhythmias (Oshik Kim et al., 2009, ReSEAT analysis report).
미세먼지에 포함된 다환방향족탄화수소(polycyclic aromatic hydrocarbon, PAH)는 세포 내로 침투되어 공통적으로 아릴 하이드로카본 수용체(Aryl hydrocarbon receptor; AhR)를 활성화 시키는 것으로 알려져 있다. AhR 활성화 기전을 통해 세포 내 활성 산소종(Reactive oxygen species; ROS)이 증가되고, 다양한 염증 매개 인자의 발현을 증가시켜 호흡기 질환을 일으키게 된다.It is known that polycyclic aromatic hydrocarbon (PAH) contained in fine dust penetrates into cells and commonly activates Aryl hydrocarbon receptor (AhR). Reactive oxygen species (ROS) in cells is increased through the AhR activation mechanism, and the expression of various inflammatory mediators is increased to cause respiratory diseases.
전세계적으로 미세먼지에 대한 호흡기 질환의 증가에 따라 세계보건기구(WHO)에서는 2013년 1군 발암물질로 분류하였으며, 우리나라도 그에 맞게 미세먼지 저감 방안 및 치료제 개발이 절실한 상황이다. 대부분의 호흡기 질환 치료제는 단일 성분의 합성 의약품으로, 미세먼지의 경우 종래 성분들이 지역적, 계절적, 시기적, 기후 환경적인 영향에 따라 달라지므로, 다양한 병리 기전에 대한 효과적인 치료가 어렵다는 문제점이 있다. 따라서 미세먼지의 발생빈도가 점차 증가되고 있는 사회적 현상으로 인해 치료제 개발 및 연구가 중요하다고 할 수 있다.Due to the increase in respiratory diseases related to fine dust worldwide, the World Health Organization (WHO) classified it as a
한편, 맥문동(Liriope platyphylla)은 음지 습한 곳에서 잘 자라고, 7월에 보라색의 꽃이 피어 10월에는 검은색 열매를 맺는 백합과에 속하는 다년생 초본식물로서, 맥문동의 효능으로 혈당강하작용, 항염증작용, 항부정맥효과, 항암작용 등이 있는 것으로 보고된 바 있다. 또한 맥문동의 주된 유효성분으로 steroid계 saponin인 ophiopogenine A, B, methylophiopogonone A, B, ophiopogonanone A, methylophiopoginanone A, B 등의 homo-isoflavonid류가 함유되어있으며, 그 외 β-sitosterol, stigmasterol, β-sitosterol glucoside, oligosaccarides 등의 다양한 polysaccharides가 괴근의 약 60%이상 함유되어 있는 것으로 보고된 바 있다. On the other hand, Liriope platyphylla is a perennial herbaceous plant belonging to the family Liliaceae that grows well in shade and humid places, blooms purple flowers in July and produces black fruits in October. It has been reported to have an action, antiarrhythmic effect, and anticancer action. In addition, as the main active ingredient of maekmundong, homo-isoflavonids such as ophiopogenine A, B, methylophiopogonone A, B, ophiopogonanone A, methylophiopoginanone A, B, which are steroid-based saponins, are contained. In addition, β-sitosterol, stigmasterol, β-sitosterol It has been reported that various polysaccharides such as glucoside and oligosaccarides are contained in more than 60% of the tuber.
또한 맥문동 추출물 이외의 천연물의 유익한 성분들을 이용하여 기능성식품 등을 제공함으로써 사회적인 문제로 부상되고 있는 미세먼지에 의해 야기되는 호흡기 질환을 예방 및 치료할 필요성이 있다.In addition, there is a need to prevent and treat respiratory diseases caused by fine dust, which is emerging as a social problem, by providing functional foods using beneficial ingredients of natural products other than maekmundong extract.
본 발명은 맥문동 추출물, 감초 추출물 및 아로니아 추출물을 유효성분으로 포함하는 미세먼지에 의한 기관지 염증 질환의 개선용 건강 기능 식품 조성물을 제공한다. The present invention provides a health functional food composition for improving bronchial inflammatory diseases caused by fine dust comprising a maekmundong extract, a licorice extract and an aronia extract as active ingredients.
상기 언급한 과제 해결을 위하여,
본 발명은, 맥문동(Liriope platyphylla) 추출물, 감초(Glycyrrhiza uralensis) 추출물 및 아로니아(Aronia) 추출물의 혼합된 추출물을 유효성분으로 포함하는 미세먼지에 의한 기관지 염증 질환의 개선용 건강 기능 식품 조성물에 있어서,
상기 맥문동(Liriope platyphylla) 추출물, 감초(Glycyrrhiza uralensis) 추출물 및 아로니아(Aronia) 추출물의 혼합된 추출물은, 맥문동, 감초 및 아로니아를 각각 건조하여 분쇄한 파우더를 각각 20g씩 혼합한 후, 70% 에탄올을 600㎖ 투입하고 100℃로 6시간 동안 가온 추출한 추출액을 여과, 감압 및 농축하여 상기 투입된 에탄올을 제거 및 동결 건조하여 35%의 수율로 수득한 맥문동(Liriope platyphylla) 추출물, 감초(Glycyrrhiza uralensis) 추출물 및 아로니아(Aronia) 추출물의 혼합된 추출물로서, NO 생성을 억제하고, 염증성 사이토카인 IL-8과 TNF-α 생성을 억제하는 것을 특징으로 하는, 미세먼지에 의한 기관지 염증 질환의 개선용 건강 기능 식품 조성물을 제공한다.In order to solve the above-mentioned problems,
The present invention provides a health functional food composition for improving bronchial inflammatory diseases caused by fine dust comprising a mixed extract of Liriope platyphylla extract, Glycyrrhiza uralensis extract and Aronia extract as an active ingredient ,
The mixed extract of the maekmundong (Liriope platyphylla) extract, the licorice (Glycyrrhiza uralensis) extract and the aronia extract is, after mixing 20g of each dried and pulverized powder of maekmundong, licorice and aronia, 70% After adding 600 ml of ethanol and heating the extract at 100° C. for 6 hours, the extracted solution was filtered, reduced pressure and concentrated to remove the added ethanol and freeze-dried to obtain a 35% yield of Liriope platyphylla extract, licorice (Glycyrrhiza uralensis) As a mixed extract of the extract and Aronia extract, it suppresses NO production and inhibits the production of inflammatory cytokines IL-8 and TNF-α. Health for improving bronchial inflammatory diseases caused by fine dust Provided is a nutraceutical composition.
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
본 발명에 따르면, 맥문동, 감초 및 아로니아를 포함하는 혼합물을 추출한 혼합된 추출물을 유효성분으로 포함하는 미세먼지에 의한 기관지 염증 질환의 개선용 건강 기능 식품 조성물은, 미세먼지에 의해 유발되는 폐의 염증을 완화시켜주며, 안정성이 뛰어나면서도 경제성이 있는 천연 기능성 소재로서, 의약품, 식품 분야에서의 소재로 활용이 가능하다.According to the present invention, a health functional food composition for the improvement of bronchial inflammatory diseases caused by fine dust comprising a mixed extract obtained by extracting a mixture containing maekmundong, licorice and aronia as an active ingredient, As a natural functional material that relieves inflammation and has excellent stability and economy, it can be used as a material in the pharmaceutical and food fields.
도 1은 맥문동 추출물, 감초 추출물, 아로니아 추출물, 맥문동과 감초 혼합 추출물, 맥문동과 아로니아 혼합 추출물, 감초와 아로니아 혼합 추출물, 맥문동과 감초 및 아로니아 혼합 추출물의 PM2.5에 의해 유발된 NO 생성을 억제하는 효과를 나타낸 그래프이다.
도 2는 맥문동 추출물, 감초 추출물, 아로니아 추출물, 맥문동과 감초 혼합 추출물, 맥문동과 아로니아 혼합 추출물, 감초와 아로니아 혼합 추출물, 맥문동과 감초 및 아로니아 혼합 추출물의 PM2.5에 의해 유발된 NO 생성을 억제하는 효과를 나타낸 그래프이다.
도 3은 맥문동 추출물, 감초 추출물, 아로니아 추출물, 맥문동과 감초 혼합 추출물, 맥문동과 아로니아 혼합 추출물, 감초와 아로니아 혼합 추출물, 맥문동과 감초 및 아로니아 혼합 추출물의 PM2.5에 의해 유발된 TNF-α 생성을 억제하는 효과를 나타낸 그래프이다.Figure 1 is maekmundong extract, licorice extract, aronia extract, maekmundong and licorice mixed extract, maekmundong and aronia mixed extract, licorice and aronia mixed extract, maekmundong and licorice and aronia mixed extract, PM2.5-induced NO It is a graph showing the effect of inhibiting the production.
Figure 2 is maekmundong extract, licorice extract, aronia extract, maekmundong and licorice mixed extract, maekmundong and aronia mixed extract, licorice and aronia mixed extract, maekmundong and licorice and aronia mixed extract induced by PM2.5 It is a graph showing the effect of inhibiting the production.
Figure 3 is maekmundong extract, licorice extract, aronia extract, maekmundong and licorice mixed extract, maekmundong and aronia mixed extract, licorice and aronia mixed extract, TNF induced by PM2.5 of maekmundong and licorice and aronia mixed extract. It is a graph showing the effect of inhibiting -α production.
본 발명은, 일면에 있어서, 맥문동(Liriope platyphylla) 추출물, 감초(Glycyrrhiza uralensis) 추출물 및 아로니아(Aronia) 추출물의 혼합된 추출물을 포함하는 건강 식품용 조성물을 제공한다.The present invention, in one aspect, provides a composition for health food comprising a mixed extract of maekmundong (Liriope platyphylla) extract, licorice (Glycyrrhiza uralensis) extract and aronia extract.
이하, 본 발명에 따른 맥문동(Liriope platyphylla) 추출물, 감초(Glycyrrhiza uralensis) 추출물 및 아로니아(Aronia) 추출물의 혼합된 추출물을 포함하는 건강 식품용 조성물을 더욱 상세히 설명한다.Hereinafter, a composition for health food including a mixed extract of Liriope platyphylla extract, Glycyrrhiza uralensis extract and Aronia extract according to the present invention will be described in more detail.
상기 맥문동(Liriope platyphylla)은 그늘지고 물기가 많은 숲속이나 산기슭에 자라는 상록성 여러해살이풀이다. 맥문동의 근연식물로는 소엽맥문동(Ophiopogon japonicus), 개맥문동(Liriope spicata) 등이 있다. 한방에서는 마른기침, 각혈, 가래 등에 사용된다.The maekmundong ( Liriope platyphylla ) is an evergreen perennial that grows in a shaded and wet forest or at the foot of a mountain. Plants related to Maekmundong include Ophiopogon japonicus and Liriope spicata . In oriental medicine, it is used for dry cough, hemoptysis, and phlegm.
상기 감초(Glycyrrhiza uralensis)는 콩과에 속하는 여러해살이풀로 중국 북동부와 시베리아, 몽골, 중국 북부 등지에 분포한다. 뿌리는 건조시켜서 한약재로 사용하는데, 그 맛이 달고, 모든 약물과 배합이 잘 되어 중화작용을 한다.The licorice ( Glycyrrhiza uralensis ) is a perennial plant belonging to the legume family and is distributed in northeastern China, Siberia, Mongolia, and northern China. The roots are dried and used as herbal medicines, and they have a sweet taste and are well combined with all drugs to neutralize.
상기 아로니아(Aronia)는 장미과의 속이다. 아로니아(영어: aronia) 또는 초크베리(영어: chokeberry)라 불리는 열매를 식용 또는 약용으로 사용하며 식용 색소의 원료로 쓰이기도 하고 관상용으로도 역시 재배된다. 탄닌 성분이 많아 바로 수확한 것은 떫은 맛이 있으나, 안토시아닌이 다량 함유되어 있어 항산화 작용이 작하며 노화를 방지할 뿐만 아니라 항암효과에도 좋은 것으로 알려져 있다.The Aronia ( Aronia ) is a genus of Rosaceae. The fruit called aronia or chokeberry is used for food or medicinal purposes, is used as a raw material for food coloring, and is also cultivated for ornamental purposes. Harvested immediately due to its high tannin content, it has an astringent taste, but contains a large amount of anthocyanins, so it has little antioxidant action and is known to be good for anti-aging as well as anti-aging.
상기 추출물은 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합 용매로 추출하여 수득할 수 있으며, 상기 저급 알코올은 에탄올 또는 메탄올일 수 있고, 보다 구체적으로 에탄올일 수 있다.The extract may be obtained by extraction with water, a C1 to C4 lower alcohol or a mixed solvent thereof, and the lower alcohol may be ethanol or methanol, and more specifically, ethanol.
본 발명에 대한 맥문동과 감초 및 아로니아의 복합 추출물은 후술하는 시험예에서 확인되는 바와 같이 미세먼지에 의한 NO 생성 억제율 시험에서 30.1%까지 억제하였고, 미세먼지 자극에 의한 폐조직내 염증성 Cytokine인 IL-8의 발현양의 증가를 크게 감소시켰다. 또한, TNF-α의 생성 억제율이 20.8%까지 억제하였다.The complex extract of maekmundong, licorice and aronia for the present invention suppressed up to 30.1% in the NO production inhibition rate test by fine dust, as confirmed in the test examples to be described later, and IL, an inflammatory cytokine in lung tissue due to fine dust stimulation The increase in the expression level of -8 was greatly reduced. In addition, the inhibition rate of TNF-α production was inhibited by 20.8%.
본 발명은 상기 제조방법으로 제조된 맥문동 유효성분을 포함한 천연물 추출물을 유효성분으로 하는 미세먼지 관련 기관지 염증 질환의 예방 및 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention and treatment of fine dust-related bronchial inflammatory diseases, comprising, as an active ingredient, a natural product extract including an active ingredient of maekmundong produced by the above manufacturing method.
상기 천연물 추출물을 조성물 총 100 중량부에 대하여 0.01 내지 100 중량부로 포함될 수 있으나, 이에 제한되는 것은 아님을 명시한다.The natural extract may be included in an amount of 0.01 to 100 parts by weight based on 100 parts by weight of the total composition, but is not limited thereto.
하나의 예시에서, 본 발명의 조성물이 약학 조성물로 활용될 경우, 투여를 위하여, 상기 기재한 유효성분 이외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 포함할 수 있다. 상기 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.In one example, when the composition of the present invention is used as a pharmaceutical composition, for administration, a pharmaceutically acceptable carrier, excipient or diluent may be included in addition to the active ingredient described above. The carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
상기 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용할 수 있다. 상세하게는 제형화할 경우 통상 사용하는 충진제, 중량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형 제제로는 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하나, 이에 한정되는 것은 아니다. 이러한 고형 제제는 상기 유효성분 외에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘 카보네이트, 수크로오스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등을 첨가하여 조제될 수 있다. 비경구 투여를 위한 제제는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조 제제 및 과제를 포함한다. 비수성 용제 및 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 오일, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로솔, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition may be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injection solutions, respectively, according to conventional methods. In detail, when formulating, it can be prepared using a diluent or excipient such as a filler, a weight agent, a binder, a wetting agent, a disintegrant, a surfactant, etc. commonly used. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such a solid preparation may be prepared by mixing at least one excipient in addition to the active ingredient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. It can be prepared by adding various excipients, for example, a wetting agent, a sweetening agent, a fragrance, a preservative, and the like, in addition to the oral liquid and liquid paraffin. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations and tasks. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As the base of the suppository, Witepsol, Macrosol, Tween 61, cacao butter, laurin oil, glycerogelatin, etc. may be used.
상기 약학 조성물의 적합한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 시간에 따라 다르지만, 당 업자에 의해 적절하게 선택될 수 있는 바, 상기 조성물의 일일 투여량은 바람직하게는 0.001 mg/kg 내지 50 mg/kg이며, 필요에 따라 일일 1회 내지 수회로 나누어 투여할 수 있다.A suitable dosage of the pharmaceutical composition varies depending on the condition and weight of the patient, the degree of disease, drug form, and time, but may be appropriately selected by those skilled in the art, and the daily dosage of the composition is preferably 0.001 mg. /kg to 50 mg/kg, and may be administered once a day or divided into several times a day as needed.
또한, 본 발명은 특정 추출 방법으로 제조된 맥문동 추출물, 감초 추출물 및 아로니아 추출물을 유효성분을 포함한 천연물 추출물을 유효성분으로서 포함하는 미세먼지 관련 호흡기 질환의 개선용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for improving fine dust-related respiratory diseases comprising, as an active ingredient, a natural product extract including an active ingredient, a maekmundong extract, a licorice extract, and an aronia extract prepared by a specific extraction method.
상기 천연물 추출물을 조성물 총 100 중량부에 대하여 0.01 내지 100 중량부로 포함될 수 있으나, 이에 제한되는 것은 아님을 명시한다.The natural extract may be included in an amount of 0.01 to 100 parts by weight based on 100 parts by weight of the total composition, but is not limited thereto.
본 발명의 조성물이 건강 기능 식품 조성물인 경우, 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스, 합성 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 또한, 건강 기능 식품 조성물은 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알코올 및 비타민 복합제 중 어느 하나의 형태일 수 있다.When the composition of the present invention is a health functional food composition, various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, it may contain the pulp for the production of natural fruit juices, synthetic fruit juices and vegetable beverages. These components may be used independently or in combination. In addition, the health functional food composition is in the form of any one of meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcohol and vitamin complex can be
또한, 상기 건강 기능 식품 조성물은 식품 첨가물을 추가로 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반 시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.In addition, the health functional food composition may further include food additives, and the suitability as a food additive is determined according to the general rules and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to the relevant standards and standards.
상기 식품첨가물공전에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산 칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀룰로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류 첨가 알칼리제, 보존료제제, 타르색소 제제 등의 혼합 제제류 등을 들 수 있다.Items listed in the Food Additives Codex, for example, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; Mixed preparations, such as a sodium preparation, an alkali agent for noodles, a preservative preparation, and a tar dye preparation, etc. are mentioned.
이때, 건강 기능 식품 조성물을 제조하는 과정에서 식품에 첨가되는 본 발명에 따른 조성물은 필요에 따라 그 함량을 적절히 가감할 수 있다.In this case, the composition according to the present invention added to food in the process of preparing the health functional food composition may appropriately increase or decrease its content as needed.
이하에서는 실시예 등을 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples and the like. These examples are only for illustrating the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .
실시예 1: 맥문동과 감초 및 아로니아 혼합 추출물의 제조Example 1: Preparation of maekmundong, licorice and aronia mixed extract
건조 분쇄된 맥문동과 감초 및 아로니아 각각 20g 혼합한 후, 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 600 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 맥문동과 감초 및 아로니아 혼합 추출물 35%의 수율로 수득하였다.After mixing 20 g of dried and pulverized maekmundong, licorice and aronia, respectively, 600 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70 was added and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol, and then freeze-dried to obtain a 35% yield of a mixed extract of maekmundong, licorice and aronia.
비교예 1: 맥문동 추출물의 제조Comparative Example 1: Preparation of maekmundong extract
건조 분쇄된 맥문동 60g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 600 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 맥문동 추출물 32%의 수율로 수득하였다.To 60 g of dry and pulverized maekmundong, 600 ml of 70% ethanol mixed with purified water and ethanol at a volume ratio of 30:70, respectively, was added, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a maekmundong extract in a yield of 32%.
비교예 2: 감초 추출물의 제조Comparative Example 2: Preparation of licorice extract
건조 분쇄된 감초 60g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 600 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 감초 추출물 33%의 수율로 수득하였다.To 60 g of dried and pulverized licorice, 600 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, was added, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a licorice extract in a yield of 33%.
비교예 3: 아로니아 추출물의 제조Comparative Example 3: Preparation of Aronia extract
건조 분쇄된 아로니아 60g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 600 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 아로니아 추출물 35%의 수율로 수득하였다.To 60 g of dry pulverized aronia, 600 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, was added, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain an aronia extract in a yield of 35%.
비교예 4: 맥문동 및 감초 혼합 추출물의 제조Comparative Example 4: Preparation of maekmundong and licorice mixed extract
건조 분쇄된 맥문동 및 감초(중량비 1:1로 혼합) 60g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 600 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 맥문동 및 감초 혼합 추출물 33%의 수율로 수득하였다.60 g of dried and pulverized maekmundong and licorice (mixed in a weight ratio of 1:1) were added with 600 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a mixed extract of Maekmundong and licorice in a yield of 33%.
비교예 5: 맥문동 및 아로니아 혼합 추출물의 제조Comparative Example 5: Preparation of maekmundong and aronia mixed extract
건조 분쇄된 맥문동 및 아로니아(중량비 1:1로 혼합) 60g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 600 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 맥문동 및 아로니아 혼합 추출물 34%의 수율로 수득하였다.To 60 g of dry pulverized maekmundong and aronia (mixed in a weight ratio of 1:1), 600 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, was added, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol, and then freeze-dried to obtain a mixed extract of maekmundong and aronia in a yield of 34%.
비교예 6: 감초 및 아로니아 혼합 추출물의 제조Comparative Example 6: Preparation of licorice and aronia mixed extract
건조 분쇄된 감초 및 아로니아(중량비 1:1로 혼합) 60g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 600 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 감초 및 아로니아 혼합 추출물 34%의 수율로 수득하였다.60 g of dry pulverized licorice and aronia (mixed at a weight ratio of 1:1), 600 ml of 70% ethanol mixed with purified water and ethanol at a volume ratio of 30:70, respectively, was added, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a mixed extract of licorice and aronia in a yield of 34%.
시험예 1: 맥문동과 감초 및 아로니아 추출물의 세포독성 확인Test Example 1: Confirmation of cytotoxicity of maekmundong, licorice and aronia extracts
맥문동과 감초 및 아로니아 추출물이 세포독성이 있는지 여부를 확인하기 위하여 다음과 같은 방법으로 실험하였다. Raw 264.7 cell 및 B2B(BEAS-2B) cell을 6.0 x 104 cells/well로 분주한 후 24시간 동안 37℃, 5% CO2 조건에서 배양하였다. 실시예 1과 비교예 1 내지 6의 추출물을 50~1,000 ㎍/ml의 농도로 처리하고 24시간 후 MTT 용액을 가하고 37℃에서 4시간 더 배양하여 생성된 formazan이 배지에 떨어져 나가지 않도록 배지를 제거하고 DMSO 100 ㎕ 분주하여 10분 동안 혼합한 후 540 nm에서 흡광도를 측정함으로써 세포 생존율을 확인하였으며, 맥문동과 감초 및 아로니아 추출물에 대한 결과를 하기 표 1에 나타내었다.In order to determine whether maekmundong, licorice and aronia extracts were cytotoxic, the experiment was conducted as follows. Raw 264.7 cells and B2B (BEAS-2B) cells were seeded at 6.0 x 10 4 cells/well and cultured at 37° C. and 5% CO 2 conditions for 24 hours. The extracts of Example 1 and Comparative Examples 1 to 6 were treated at a concentration of 50 to 1,000 μg/ml, and after 24 hours, the MTT solution was added and cultured at 37° C. for 4 hours, and the formed formazan was removed so that the medium did not fall off the medium. Then, 100 μl of DMSO was dispensed and mixed for 10 minutes, and the cell viability was confirmed by measuring the absorbance at 540 nm.
하기 표 1 내지 표 7에 나타난 바와 같이, 맥문동과 감초 및 아로니아 추출물은 50 내지 400(㎍/ml)에서 세포 독성이 나타나지 않음을 확인하였다.As shown in Tables 1 to 7 below, it was confirmed that maekmundong, licorice and aronia extracts did not show cytotoxicity at 50 to 400 (㎍/ml).
시험예 2: 맥문동과 감초 및 아로니아 추출물의 NO 생성 억제능 평가 Test Example 2: Evaluation of NO production inhibitory ability of maekmundong, licorice and aronia extracts
상기 시험예 1에서 확인한 맥문동과 감초 및 아로니아 추출물을 세포독성이 없는 농도인 100~400 ㎍/ml로 처리하여 NO 생성능 억제능을 다음과 같은 방법으로 평가하였다. The ability to inhibit NO production was evaluated in the following manner by treating the extracts of maekmundong, licorice and aronia, which were confirmed in Test Example 1, at a concentration of 100 to 400 μg/ml without cytotoxicity.
Raw 264.7 cell을 96 well plate에 6 x 104 cells/well로 분주한 후, 24시간 동안 37℃, 5% CO2 조건에서 배양하였다. 맥문동과 감초 및 아로니아 추출물을 100, 200, 400 ㎍/ml의 농도로 처리하고 미세먼지 표준품을 처리한 후, 다시 24시간 동안 배양하였다. 그 후 세포 배양액을 Griess reagent와 1:1로 혼합하고 540 nm에서 흡광도를 측정하여 NO 생성을 측정하였고, 그 결과를 도 1에 나타내었다.Raw 264.7 cells were aliquoted in a 96-well plate at 6 x 10 4 cells/well, and then cultured at 37°C and 5% CO 2 conditions for 24 hours. Maekmundong, licorice and aronia extracts were treated at concentrations of 100, 200, and 400 μg/ml, treated with fine dust standards, and then cultured for 24 hours again. Thereafter, the cell culture solution was mixed with Griess reagent 1:1 and absorbance was measured at 540 nm to measure NO production, and the results are shown in FIG. 1 .
도 1에 나타낸 바와 같이, 맥문동과 감초 및 아로니아 추출물은 농도 의존적으로 NO 생성 억제 효과를 나타내었고, 하나의 추출물만 처리하였을 때보다 혼합 추출물이 더 우수한 NO 생성 억제 효과를 나타내었다.As shown in Figure 1, the extracts of maekmundong, licorice and aronia showed a concentration-dependent NO production inhibitory effect, and the mixed extract exhibited a better NO production inhibitory effect than when only one extract was treated.
시험예 3: 맥문동과 감초 및 아로니아 추출물의 IL-8 생성 억제능 평가Test Example 3: Evaluation of IL-8 production inhibitory ability of maekmundong, licorice and aronia extracts
상기 시험예 1에서 확인한 맥문동과 감초 및 아로니아 추출물을 세포독성이 없는 농도인 100~400 ㎍/ml로 처리하여 IL-8 생성 억제능을 다음과 같은 방법으로 평가하였다.The ability to inhibit IL-8 production was evaluated by treating the extracts of maekmundong, licorice and aronia, which were confirmed in Test Example 1, at a concentration of 100-400 μg/ml, which is non-cytotoxic.
96 well plate에 B2B cell을 6 x 104 cells/well로 분주한 후, 24시간 동안 37℃, 5% CO2 조건에서 배양하였다. 맥문동과 감초 및 아로니아 추출물을 100, 200, 400 ㎍/ml의 농도로 처리하고 미세먼지 표준품을 처리한 후, 다시 24시간 동안 배양하였다. 그 후 세포 배양액을 취하여 IL-8의 정량에 대한 ELISA kit를 이용하여 정량하였으며, 맥문동과 감초 및 아로니아 추출물에 대한 결과를 도 2에 나타내었다.B2B cells were aliquoted in a 96-well plate at 6 x 10 4 cells/well, and then cultured at 37° C. and 5% CO 2 conditions for 24 hours. Maekmundong, licorice and aronia extracts were treated at concentrations of 100, 200, and 400 μg/ml, treated with fine dust standards, and then cultured for 24 hours again. Thereafter, the cell culture medium was taken and quantified using an ELISA kit for the quantification of IL-8.
도 2에 나타낸 바와 같이, 맥문동과 감초 및 아로니아 추출물은 농도 의존적으로 IL-8 생성 억제효과를 나타내었고, 하나의 추출물만 처리하였을 때보다 혼합 추출물이 더 우수한 억제 효과를 나타내었다.As shown in FIG. 2 , the extracts of maekmundong, licorice and aronia showed an inhibitory effect on IL-8 production in a concentration-dependent manner, and the mixed extract showed a better inhibitory effect than when only one extract was treated.
시험예 4: 맥문동과 감초 및 아로니아 추출물의 TNF-α 생성 억제능 평가Test Example 4: Evaluation of TNF-α production inhibitory ability of maekmundong, licorice and aronia extracts
상기 시험예 1에서 확인한 맥문동과 감초 및 아로니아 추출물을 세포독성이 없는 농도인 100~400 ㎍/ml로 처리하여 TNF-α 생성 억제능을 다음과 같은 방법으로 평가하였다.The ability to inhibit TNF-α production was evaluated by treating the extracts of maekmundong, licorice and aronia, which were confirmed in Test Example 1, at a concentration of 100 to 400 μg/ml without cytotoxicity.
96 well plate에 B2B cell을 6 x 104 cells/well로 분주한 후, 24시간 동안 37℃, 5% CO2 조건에서 배양하였다. 맥문동과 감초 및 아로니아 추출물을 100, 200, 400 ㎍/ml의 농도로 처리하고 미세먼지 표준품을 처리한 후, 다시 24시간 동안 배양하였다. 그 후 세포 배양액을 취하여 TNF-α의 정량에 대한 ELISA kit를 이용하여 정량하였으며, 맥문동과 감초 및 아로니아 추출물에 대한 결과를 도 3에 나타내었다.B2B cells were aliquoted in a 96-well plate at 6 x 10 4 cells/well, and then cultured at 37° C. and 5% CO 2 conditions for 24 hours. Maekmundong, licorice and aronia extracts were treated at concentrations of 100, 200, and 400 μg/ml, treated with fine dust standards, and then cultured for 24 hours again. Thereafter, the cell culture medium was taken and quantified using an ELISA kit for quantitation of TNF-α, and the results for maekmundong, licorice and aronia extracts are shown in FIG. 3 .
도 3에 나타낸 바와 같이, 맥문동과 감초 및 아로니아 추출물은 농도 의존적으로 TNF-α 생성 억제효과를 나타내었고, 하나의 추출물만 처리하였을 때보다 혼합 추출물이 더 우수한 억제 효과를 나타내었다.As shown in FIG. 3 , the extracts of maekmundong, licorice and aronia showed a concentration-dependent inhibitory effect on TNF-α production, and the mixed extract showed a better inhibitory effect than when only one extract was treated.
Claims (7)
상기 맥문동(Liriope platyphylla) 추출물, 감초(Glycyrrhiza uralensis) 추출물 및 아로니아(Aronia) 추출물의 혼합된 추출물은, 맥문동, 감초 및 아로니아를 각각 건조하여 분쇄한 파우더를 각각 20g씩 혼합한 후, 70% 에탄올을 600㎖ 투입하고 100℃로 6시간 동안 가온 추출한 추출액을 여과, 감압 및 농축하여 상기 투입된 에탄올을 제거 및 동결 건조하여 35%의 수율로 수득한 맥문동(Liriope platyphylla) 추출물, 감초(Glycyrrhiza uralensis) 추출물 및 아로니아(Aronia) 추출물의 혼합된 추출물로서, NO 생성을 억제하고, 염증성 사이토카인 IL-8과 TNF-α 생성을 억제하는 것을 특징으로 하는, 미세먼지에 의한 기관지 염증 질환의 개선용 건강 기능 식품 조성물.
In the health functional food composition for improving bronchial inflammatory diseases caused by fine dust, the composition comprising a mixed extract of Liriope platyphylla extract, Glycyrrhiza uralensis extract and Aronia extract as an active ingredient,
The mixed extract of the maekmundong (Liriope platyphylla) extract, the licorice (Glycyrrhiza uralensis) extract and the aronia extract is, after mixing 20g of each dried and pulverized powder of maekmundong, licorice and aronia, 70% After adding 600 ml of ethanol and heating the extract at 100° C. for 6 hours, the extracted solution was filtered, reduced pressure and concentrated to remove the added ethanol and freeze-dried to obtain a 35% yield of Liriope platyphylla extract, licorice (Glycyrrhiza uralensis) As a mixed extract of the extract and Aronia extract, it suppresses NO production and inhibits the production of inflammatory cytokines IL-8 and TNF-α. Health for improving bronchial inflammatory diseases caused by fine dust nutraceutical composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200027571A KR102297398B1 (en) | 2020-03-05 | 2020-03-05 | Composition for health food for improving of respiratory diseases caused by fine dust comprising extract of Liriope platyphylla, Glycyrrhiza uralensis and Aronia as an effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200027571A KR102297398B1 (en) | 2020-03-05 | 2020-03-05 | Composition for health food for improving of respiratory diseases caused by fine dust comprising extract of Liriope platyphylla, Glycyrrhiza uralensis and Aronia as an effective component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102297398B1 true KR102297398B1 (en) | 2021-09-02 |
Family
ID=77794471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200027571A KR102297398B1 (en) | 2020-03-05 | 2020-03-05 | Composition for health food for improving of respiratory diseases caused by fine dust comprising extract of Liriope platyphylla, Glycyrrhiza uralensis and Aronia as an effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102297398B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101756284B1 (en) * | 2016-04-01 | 2017-07-26 | 중부대학교 산학협력단 | Composition for improving inflammatory diseases containing White Ginseng Complex Extract |
| KR20180091311A (en) | 2017-02-06 | 2018-08-16 | 주식회사 한국인삼공사 | Composition for Respiratory Symptoms Containing Red Ginseng Extract |
-
2020
- 2020-03-05 KR KR1020200027571A patent/KR102297398B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101756284B1 (en) * | 2016-04-01 | 2017-07-26 | 중부대학교 산학협력단 | Composition for improving inflammatory diseases containing White Ginseng Complex Extract |
| KR20180091311A (en) | 2017-02-06 | 2018-08-16 | 주식회사 한국인삼공사 | Composition for Respiratory Symptoms Containing Red Ginseng Extract |
Non-Patent Citations (3)
| Title |
|---|
| Young-Cheol Lee 외. Liriopis tuber inhibit OVA-induced airway inflammation and bronchial hyperresponsiveness in murine model of asthma. Journal of Ethnopharmacology Vol. 101, 2005, pp. 144-152* * |
| 장보윤 외. 호흡기 증상에 대한 복합제 HAE의 완화 효과. 생약학회지. 46(4), 2015, pp. 334-341 * |
| 정해준 외. 맥문동(麥門冬)이 천식유발 cytokine 분비와 호산구 chemotaxis에 미치는 영향. 대한한방성인병학회지. Vol. 10(1), 2005 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6640392B2 (en) | Obesity control composition | |
| KR100771524B1 (en) | Composition for improving liver function comprising herbal mixture extract | |
| KR101705547B1 (en) | Composition for antioxidant or anticancer or antidiabete or antimicrobial containing balloon flower extract | |
| KR102366919B1 (en) | Functional health food composition for inhibiting muscle reduction comprising a mixed extract of mulberry twig, Eucommia bark, Acanthopanax, and black bean | |
| KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
| KR100771525B1 (en) | Composition for removing hangover comprising herbal mixture extract | |
| KR101831981B1 (en) | Composition for preventing, improving or treating cancer comprising Sageretia thea extract or its fraction as effective component | |
| KR101416191B1 (en) | Pharmaceutical composition for preventing or treating cancer comprising extract of Jeju traditional citrus Palsac, Dangyusa or Iyegam as effective component | |
| KR102297398B1 (en) | Composition for health food for improving of respiratory diseases caused by fine dust comprising extract of Liriope platyphylla, Glycyrrhiza uralensis and Aronia as an effective component | |
| KR100462788B1 (en) | Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory | |
| KR101075554B1 (en) | Composition for the prevention and treatment of postmenopausal syndrome containing extracts or fractions of Aceriphyllum rossii as an effective ingredient | |
| KR100919134B1 (en) | Extract of antiobestic ginseng with anti-obesity effect comprising high concentration of less polar ginsenoid and method of preparing the same | |
| KR102355104B1 (en) | Pharmaceutical and functional food composition comprising complex extract of Brassica rapa for prevention or treatment of respiratory disease | |
| KR102355106B1 (en) | Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease | |
| KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
| KR101525877B1 (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
| KR101520417B1 (en) | Composition comprising herbal mixture extract for treating or preventing thyroid cancer | |
| KR100417243B1 (en) | Pharmaceutical composition comprising the extract of Phyllostachys nigra var. henonis having anti-inflammatory activity for the prevention and treatment of inflammatory disease | |
| KR20120000250A (en) | Composition for anticancer drugs comprising an extract of boehmeria spicata thunb | |
| KR20200101114A (en) | Food composition comprising Chrysanthemum zawadskii var extract | |
| KR101877413B1 (en) | Composition containing Melandrii Herba extract reducing lipid accumulation as effective component | |
| KR20100008220A (en) | Composition for preventing and treating colon cancer containing extract of mushroom and herb medicine | |
| KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
| KR102087165B1 (en) | Pharmaceutical composition for Anti-oxidative or Anti-inflammatory comprising extract processed by Enzymatic hydrolysis of the Bark of Eleutherococcus sessiliflorus | |
| KR101596006B1 (en) | Composition for Prevention and Treatment of Cardiovascular Diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |